Supernus Pharmaceuticals Down Nearly 10%

Supernus Pharmaceuticals SUPN is trading lower on the session. The stock has been trading significantly higher in the past 2 days after the company received FDA approval for Trokendi. Supernus Pharmaceuticals is focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its two epilepsy product candidates are SPN-538 and Epliga. Epliga is in Phase III clinical trials. Supernus Pharmaceuticals is currently trading at $10.40, a loss of $1.08 or 9.41%.